Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Apr 19;49(4):1601348.
doi: 10.1183/13993003.01348-2016. Print 2017 Apr.

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD

Denis E O'Donnell  1 , Richard Casaburi  2 , Peter Frith  3 , Anne Kirsten  4 , Dorothy De Sousa  5 , Alan Hamilton  5 , Wenqiong Xue  6 , François Maltais  7
Affiliations
Clinical Trial

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD

Denis E O'Donnell et al. Eur Respir J. .

Abstract

Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease.For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium/olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler. Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75% of peak incremental work rate after 6 weeks (2 h post-dose).295 and 291 patients were treated in MORACTO 1 and 2, respectively. Tiotropium/olodaterol 2.5/5 and 5/5 µg provided significant improvements in inspiratory capacity versus placebo and monotherapies (p<0.0001), and significant improvements in exercise endurance time versus placebo (p<0.0001). Intensity of breathing discomfort was reduced following both doses of tiotropium/olodaterol versus placebo (p<0.0001).Once-daily tiotropium/olodaterol yielded improvements in lung hyperinflation versus placebo and statistically significant improvements versus monotherapies. Tiotropium/olodaterol also showed improvements in dyspnoea and exercise tolerance versus placebo but not consistently versus monotherapies.

Trial registration: ClinicalTrials.gov NCT01533935 NCT01533922.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Figures

FIGURE 1
FIGURE 1
Study design. O: olodaterol; T: tiotropium; CWRCE: constant work-rate cycle ergometry; IC: inspiratory capacity; EET: exercise endurance time. Incomplete-crossover study: four of five treatments given once daily in random order (placebo, O 5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg), all via the Respimat inhaler.
FIGURE 2
FIGURE 2
Participant flow (combined studies). O: olodaterol; T: tiotropium; IC: inspiratory capacity; EET: exercise endurance time. As these were incomplete-crossover studies, patients received four out of five possible treatments.
FIGURE 3
FIGURE 3
Adjusted mean±se inspiratory capacity (IC) pre-exercise, at isotime and at end-exercise after 6 weeks (combined studies). O: olodaterol; T: tiotropium. As each patient only received four out of five possible treatments, isotimes differ between treatments.
FIGURE 4
FIGURE 4
Adjusted geometric mean±se exercise endurance time (EET) during constant work-rate cycle ergometry after 6 weeks of treatment (combined studies). O: olodaterol; T: tiotropium. *: p<0.05; **: p<0.01; ***: p<0.0001.
FIGURE 5
FIGURE 5
Adjusted mean±se intensity of breathing discomfort (Borg scale) after 6 weeks at pre-exercise, isotime and end-exercise (combined studies). O: olodaterol; T: tiotropium. NS: nonsignificant.
See this image and copyright information in PMC

Comment in

References

    1. ZuWallack R. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. COPD 2007; 4: 293–297. - PubMed
    1. Jones PW. Activity limitation and quality of life in COPD. COPD 2007; 4: 273–278. - PubMed
    1. O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007; 4: 225–236. - PubMed
    1. Garcia-Rio F, Lores V, Mediano O, et al. . Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009; 180: 506–512. - PubMed
    1. Watz H, Pitta F, Rochester CL, et al. . An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014; 44: 1521–1537. - PubMed

Publication types

Associated data